Novel Retinal Laser Therapies

Xie, Xinyi; Liu, Qinghuai; Paulus, Yannis M.

doi:10.17554/j.issn.2409-5680.2018.04.81

Cited by 5 publications

(2 citation statements)

References 48 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Endpoint Management (EpM) laser is a newer non-damaging laser therapy designed to deliver the appropriate laser power to the macula even in the absence of visible tissue changes. The algorithm titrates laser power to cause changes in heat shock proteins (HSPs) without leading to permanent scarring and damage to the macula [15]. Stimulation of retinal pigment epithelial (RPE) cells is thought to increase the expression of heat shock proteins, which are chaperones for protein refolding, inhibit apoptosis, and decrease inflammation, overall improving the RPE function and reducing macular edema [16][17][18].…”

Section: Introductionmentioning

confidence: 99%

Adjunct Nondamaging Focal Laser Reduces Intravitreal Injection Burden in Diabetic Macular Edema

Azzouz,

Durrani,

Zhou

et al. 2023

Photonics

View full text Add to dashboard Cite

This study aims to determine the impact of adjunct nondamaging focal laser therapy on the number of anti-vascular endothelial growth factor (anti-VEGF) injections and visual acuity (VA) and imaging in patients with diabetic macular edema (DME). A retrospective analysis of 18 eyes of 14 patients with DME treated with a single session of the PASCAL 532 nm Synthesis Photocoagulator with Endpoint Management was conducted. Demographic data, VA, imaging, laser parameters, and anti-VEGF injection burden six months before and after treatment were collected. Wilcoxon Signed-rank tests were used to assess changes in VA and injection burden before and after treatment. The mean number of intravitreal injections in the six-month period prior to laser treatment was 3.39 ± 2.57 injections compared to 2.33 ± 2.40 injections following laser treatment (p = 0.02). There was no significant difference between the mean VA on the day of treatment logMAR VA of 0.38 ± 0.27 (approx. Snellen equivalent 20/50) and the visual acuity on the most recent follow-up 6 months after laser logMAR VA of 0.35 ± 0.32 (approx. Snellen equivalent 20/40) (p = 0.34). There was also no significant difference in OCT central macular thickness before (311 µm) compared to 6 months after (301 µm, p = 0.64). Adjunct focal macular laser therapy is associated with a statistically and clinically significant decrease in the number of intravitreal injections required in the six-month period immediately following treatment, without compromising visual acuity or macular thickness. Nondamaging focal laser has the potential to alleviate the burden of injections for both patients and clinics.

show abstract

Section: Introductionmentioning

confidence: 99%

Adjunct Nondamaging Focal Laser Reduces Intravitreal Injection Burden in Diabetic Macular Edema

Azzouz,

Durrani,

Zhou

et al. 2023

Photonics

View full text Add to dashboard Cite

show abstract

“…In addition, the size of the laser burn increases by 16% every year for up to 4 years. 12 Pattern scanning laser (PASCAL) provides subthreshold therapy using low energy and short pulses while alleviating DME and reducing side effects. 13 Using nondamaging laser technology, it is possible to induce biochemical stimulation of the retina without creating thermal tissue damage during treatment.…”

Section: Introductionmentioning

confidence: 99%

Treatment results of nondamaging retinal laser therapy in diabetic macular edema

Gültekin

2022

Ophthalmol Eye Dis

View full text Add to dashboard Cite

Background: Subthreshold nondamaging retinal laser therapy (NRT) provides a greater safety profile than conventional laser methods, but more data is needed on the efficacy and safety of subthreshold NRT in diabetic macular edema. Purpose: To evaluate the efficacy and safety of NRT for the treatment of clinically significant macular edema (CSME) that is partially responsive or resistant to intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment. Methods: This was a retrospective case series study. Fifty eyes of 38 diabetic patients with CSME previously treated with at least 6-monthly intravitreal bevacizumab injections with/without intravitreal Ozurdex therapy were evaluated. The patients received 577-nm yellow wavelength laser therapy with PASCAL laser system (Topcon Medical Laser Systems, Santa Clara, CA, USA). Best-corrected visual acuity (BCVA) and central subfield thickness (CST) were evaluated before and 1, 3, 6, 12 and 24 months after laser treatment. Results: Baseline mean CST was 368.06 ± 86.9 µm. The mean CST values at the 1-, 3-, 6-, 12-, and 24-month visits were 336.93 ± 79.8, 352.40 ± 113.5, 336.36 ± 109.3, 325.10 ± 104 µm, and 310.08 ± 84.7 µm, respectively. The mean CST decreased significantly at the first ( p = 0.002) and second year visits ( p < 0.001) when compared with pretreatment values. Although visual acuity was improved at the first year compared with baseline, this difference was not statistically significant ( p = 0.03). There was no significant difference in visual acuities between pretreatment and posttreatment visits. During 24-month follow-up, while 37 eyes were treated with [mean: 5.7 ± 3.4 (1–14)] intravitreal anti-VEGF injections, 3 eyes were administered single-dose intravitreal steroids. Additional intravitreal injections were not required in 10 (20%) eyes. Conclusion: NRT is effective by itself or in combination with anti-VEGF agents in diabetic macular edema that is partially responsive or resistant to previous intravitreal injections. T role in treating this disorder should be assessed in more detail with prospective controlled studies.

show abstract

Laser Therapy to Treat Diabetic Macular Edema

2024

Laser Therapy in Healthcare

View full text Add to dashboard Cite

Novel Retinal Laser Therapies

Cited by 5 publications

References 48 publications

Adjunct Nondamaging Focal Laser Reduces Intravitreal Injection Burden in Diabetic Macular Edema

Adjunct Nondamaging Focal Laser Reduces Intravitreal Injection Burden in Diabetic Macular Edema

Treatment results of nondamaging retinal laser therapy in diabetic macular edema

Laser Therapy to Treat Diabetic Macular Edema

Contact Info

Product

Resources

About